VolitionRx Limited (VNRX)
After hours:
| Previous Close | 0.7200 |
| Open | 0.7400 |
| Bid | 0.7775 x 900 |
| Ask | 0.7571 x 1400 |
| Day's Range | 0.7177 - 0.8201 |
| 52 Week Range | 0.5500 - 1.9300 |
| Volume | |
| Avg. Volume | 190,465 |
| Market Cap | 60.402M |
| Beta (5Y Monthly) | 1.35 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.5000 |
| Earnings Date | May 13, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.73 |
PR NewswireVolitionRx Limited Schedules First Quarter 2024 Earnings Conference Call and Business Update
VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will host a conference call on Tuesday, May 14 at 8.30 a.m. U.S. Eastern Time to discuss its financial and operating results for the first quarter 2024, in addition to providing a business update. Details of this event can also be found below.
PR NewswireNu.Q® Vet Cancer Test launched in-clinic in U.S. and Europe through Antech
VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has announced that its Nu.Q® Vet Cancer Test is now available in-clinic to veterinarians across the U.S and Europe through Antech, a leading veterinary diagnostics company.
Insider MonkeyVolitionRx Limited (AMEX:VNRX) Q4 2023 Earnings Call Transcript
VolitionRx Limited (AMEX:VNRX) Q4 2023 Earnings Call Transcript March 26, 2024 VolitionRx Limited isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, ladies and gentlemen, and thank you for standing by. Welcome to VolitionRx Limited Fourth Quarter and Full […]
